DATE: May 15, 2019
TIME: 9:00am PDT, 11:00am CDT, 12:00pm EDT
Hepatitis B infections remain a significant global healthcare burden resulting in 887,000 deaths in 2015. Clinical laboratories can have a measurable impact in improving liver disease care while maximizing healthcare systems efficiencies through the application of high-quality diagnostic technologies. Abbott Laboratories legacy of innovation in hepatitis diagnostics spans decades and continues with the development of an automated assay for the detection of serum HBV pregenomic RNA (pgRNA). Serum HBV pgRNA has been proposed as a marker of HBV cccDNA activity and may be a useful clinical biomarker in evaluating chronic hepatitis B patient response to current nucleoside analogue therapy and aid in the development of novel therapeutic regimens. pgRNA kinetics in conjunction with other molecular and serologic tests may provide insights which aid in the staging and management of people with chronic HBV.
- Understand the impact and healthcare burden of Global Hepatitis B Infections.
- Discover how efforts in assay development led to pregenomicRNA (pgRNA) as an indicator of Hepatis B activity.
- Comprehend the potential applications of pgRNA in therapy response monitoring.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.